Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3Recruiting 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 14Gastrointestinal 13Gynecologic 7Thoracic 5Head & Neck 5Dermatologic 5Tumor-Agnostic 3CNS 3Sarcoma 2Genitourinary 2Other solid neoplasm 1

Conditions

Neoplasms 3

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Indocyanine Green × Tumor-Agnostic × Clear all
NCT02280954 2018-03-20

818012

University of Pennsylvania

Phase 1 Completed
48 enrolled
Tumor-Agnostic

Neoplasms

NCT02621268 2018-03-20

ICG

University of Pennsylvania

Phase 1 Completed
48 enrolled
Tumor-Agnostic

Neoplasms

NCT01884584 2017-03-09

Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer

Emory University

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡